길랭 바레 증후군 시장 : 치료 유형별, 유형별, 성별, 연령대별, 최종사용자별 - 세계 예측

Global Guillain-Barre Syndrome (GBS) Market will record a 4.6% CAGR from 2024 to 2032, driven by growing patient awareness. Greater awareness among patients and advocacy groups about Guillain-Barre Syndrome (GBS) symptoms, treatment options, and supportive care plays a pivotal role in its management. This heightened awareness leads to earlier recognition of symptoms, facilitating prompt medical intervention and improving patient outcomes.

As per the National Institute of Neurological Disorders and Stroke (NINDS) report, better patient awareness and advocacy efforts have led to a 20% upsurge in early diagnosis and treatment of Guillain-Barre Syndrome, significantly improving patient outcomes and management.

Advocacy efforts contribute to increased funding for research into GBS therapies and support services, enhancing overall patient care. By educating both patients and healthcare providers, advocacy groups help ensure that individuals affected by GBS receive timely and appropriate treatment, thus potentially reducing the severity and duration of the condition's impact on patients' lives.

The overall Guillain-Barre syndrome (GBS) market is classified based on treatment type, gender, type, end-user, age group, and region.

The supportive treatments segment will exhibit a robust CAGR through 2032. As awareness of GBS increases, so does the recognition of the need for comprehensive supportive care to manage its symptoms effectively. Additionally, advancements in medical technology and therapeutic approaches have expanded the range of supportive treatments available, offering patients more options for alleviating discomfort and enhancing recovery. Moreover, with healthcare systems emphasizing holistic patient care, there is a growing emphasis on providing comprehensive support throughout the treatment journey, driving the demand for supportive therapies tailored to the unique needs of GBS patients.

The chronic inflammatory demyelinating polyneuropathy (CIDP) segment will garner a considerable Guillain-Barre syndrome (GBS) market share by 2032, owing to better diagnostic capabilities, leading to higher identification rates of CIDP cases. The overlap in treatment protocols for CIDP and GBS, both involving immune-modulating therapies, has driven the need for specialized care in this segment. Additionally, enhanced patient outcomes with early and accurate diagnosis encourage proactive management, spurring the demand for targeted therapies. Moreover, rising healthcare investments in neurological research further bolster the development and availability of effective treatments for these conditions.

Europe Guillain-Barre syndrome (GBS) market will register a noteworthy CAGR from 2024 to 2032, because of the aging population, which is more susceptible to autoimmune disorders. Additionally, increased investments in healthcare infrastructure and research in Europe have improved access to advanced medical care and innovative therapies. Public health initiatives focused on early diagnosis and comprehensive patient care contribute to the rising demand. Heightened awareness campaigns and support from European neurological associations are guiding more patients to seek timely and effective treatments, boosting the market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of GBS
    • 3.2.1.2 Growing awareness for rare disease treatment
    • 3.2.1.3 Government supporting policies and funding
    • 3.2.1.4 Expanding R&D investment
    • 3.2.1.5 Advancements in diagnostics and treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects of treatments
    • 3.2.2.2 Regulatory and reimbursement challenges
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Competitive analysis of major market players
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 First-line treatment
  • 5.2.1 Intravenous immunoglobulin (IVIG)
  • 5.2.2 Plasma exchange (Plasmapheresis)
• 5.3 Supportive treatment

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Acute inflammatory demyelinating polyneuropathy (AIDP)
• 6.3 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• 6.4 Miller fisher syndrome (MFS)
• 6.5 Acute motor axonal neuropathy (AMAN)
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Below 20 years
• 8.3 21-40 years
• 8.4 41-59 years
• 8.5 60 and above

Chapter 9 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Clinics
• 9.4 Rehabilitation centers
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Biogen Inc.
• 11.3 Cadila Healthcare Limited
• 11.4 CSL Behring LLC
• 11.5 F.Hoffmann-La Roche Ltd.
• 11.6 GSK plc
• 11.7 Grifols SA
• 11.8 LGM Pharmaceuticals, Inc.
• 11.9 Merck & Co., Inc.
• 11.10 Octapharma AG
• 11.11 Pfizer Inc.
• 11.12 Takeda Pharmaceutical Company Limited